A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB–IIIB Lung Squamous Cell Carcinoma

ABSTRACT This phase II trial investigated perioperative camrelizumab plus neoadjuvant chemotherapy for patients with stage IIB–IIIB lung squamous cell carcinoma (LUSC) and explored predictive biomarkers of treatment response. Patients received neoadjuvant camrelizumab (200 mg, Day 1) in combination...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Mingming Hu, Shuku Liu, Yi Han, Feng Wang, Yang Liu, Baohua Lu, Hongxia Li, Yuan Gao, Ying Wang, Wei Yang, Kang Shi, Bo Xiao, Qunhui Wang, Juan Du, Haifeng Lin, Xiaomi Li, Chong Wang, Tongmei Zhang
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Wiley 2026-07-01
Cyfres:	MedComm
Pynciau:	camrelizumab lung squamous cell carcinoma major pathological response neoadjuvant immunochemotherapy perioperative immunotherapy
Mynediad Ar-lein:	https://doi.org/10.1002/mco2.70793
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!